

Review Article

AI-enabled Diagnostics and Monitoring in Nanomedicine



Odii Peter Egwuatu^{1,*} | Merit Oluchi Ori² | Humphrey Sam Samuel³ | Francis-Dominic Makong Ekpan⁴

¹Department of Anatomy, Ebonyi State University, Abakaliki, Nigeria

²Department of Microbiology, Federal University of Technology Owerri, Imo State, , Nigeria

³Department of Chemical Sciences, Federal University Wukari, Taraba State, Nigeria

⁴Department of Biotechnology, Federal University of Technology Owerri, Nigeria

Use your device to scan and read
the article online



Citation O.P. Egwuatu, M.O. Ori, H.S. Samuel, F.M. Ekpan, **AI-enabled Diagnostics and Monitoring in Nanomedicine**. *Eurasian J. Sci. Technol.*, 2024, 4(3), 208-229.

<https://doi.org/10.48309/EJST.2024.426725.1116>

**Article info:**

Received: 2023-11-28

Accepted: 2024-01-02

Available Online: 2024-02-04

ID: EJST-2311-1116

Checked for Plagiarism: Yes

Checked Language Editor: Yes

Keywords:

Artificial Intelligence, Diagnostics, Monitoring, Nanomedicine, AI-driven drug discovery, drug delivery.

ABSTRACT

This review article explores the transformative impact of AI in the field of nanomedicine, specifically focusing on AI-enabled diagnostics and monitoring. Nanomedicine has emerged as a promising approach for improving medical imaging, drug delivery, diagnostics, and therapy, and AI has become a disruptive force that enhances the precision, efficiency, and personalization of healthcare solutions. We delve into the role of AI in designing and optimizing nanomaterials, drug delivery systems, and combinatorial nanomedicine administration. AI's potential to examine vast datasets, discover patterns and predict behaviour in biological systems is discussed. The paper also highlights the vital role of AI-driven nanosensors in the real-time monitoring of biomarkers within the human body. Interdisciplinary collaboration in healthcare is emphasized, as it is essential for addressing complex challenges and achieving global health goals. The article concludes by exploring how AI has revolutionized surgical planning, anatomical modelling, and virtual anatomy education in the context of nanomedicine. Overall, this review demonstrates the significant potential of AI-enabled diagnostics and monitoring in nanomedicine to revolutionize healthcare.

*Corresponding Author: Odii Peter Egwuatu, odiipeter89@gmail.com

Introduction

Nanomedicine, the convergence of nanotechnology and healthcare, has witnessed remarkable advancements in recent years, transforming the landscape of diagnosis and treatment [1]. In this era of precision medicine, where tailoring healthcare solutions to individual patients is paramount, artificial intelligence [AI] has emerged as a pivotal tool, augmenting our ability to diagnose diseases and monitor therapeutic interventions. The synergy of nanomedicine and AI promises not only early disease detection but also the delivery of personalized, targeted treatments [2]. The nanomedicine foundation lies in the utilization of nanoparticles and nanodevices at the nanoscale to interact with biological systems at a molecular level. These innovative technologies have paved the way for enhanced imaging, targeted drug delivery, and real-time monitoring of health parameters. However, the sheer volume of data generated at this scale necessitates advanced computational techniques for analysis and interpretation. AI, in the form of machine learning and deep learning algorithms, has emerged as an indispensable partner in processing and deciphering this complex data. It enables the identification of disease biomarkers, expedites drug discovery processes, and empowers the development of intelligent diagnostic tools. The fusion of nanomedicine and AI is poised to revolutionize the healthcare industry, ushering in an era of predictive and personalized medicine [3]. While previous research has delved into the intersections of AI and medical diagnostics, focused exploration into the nuanced applications within nanomedicine remains largely uncharted territory [4]. Existing studies often provide broad overviews or concentrate on singular aspects, but there is a palpable need for an in-depth analysis that synthesizes the latest advancements, challenges, and

prospects specific to the nanomedicine domain [5]. Several critical issues emerge from the intersection of AI with nanomedicine, including but not limited to, data integration challenges at the nanoscale, ensuring the safety and efficacy of AI-driven nano-devices, ethical considerations surrounding patient data and autonomy, and the translation of AI findings into clinically actionable insights. Addressing these issues is paramount to harnessing the full potential of AI in advancing diagnostics and monitoring within nanomedicine [6]. This review encompasses a comprehensive exploration of the field, from the historical context and foundational principles of nanomedicine [7] to the latest AI technologies propelling healthcare into a new era [8].

Foundations of Nanomedicine

Nanomedicine is among the numerous opportunities and advances promoted by nanotechnology. The definitions of nanomedicine accepted today were established by the National Institutes of Health of the United States and the European Science Foundation, which define nanomedicine as the “science that uses nanomaterials to the development of diagnosis, treatment and prevention of specific medical application [9,10]. The advancements of this technology have promoted innovations in different medical fields, including controlled drug delivery, biomarkers, molecular imaging, and biosensing[11]. Nanomedicine can make significant contributions to the health industry, including the areas of medicine, pharmaceutical sciences, and dentistry. Innovative methods for identifying, treating, and preventing diseases are being developed in the interdisciplinary field of nanomedicine. It involves interacting with biological systems at the molecular level using nanoscale materials like nanoparticles and nanodevices [12]. The following are some foundations of nanomedicine:

- i. *Drug delivery*: By targeting specific organs in the body with nanoparticles, medications can be administered more effectively and with fewer side effects. This is accomplished using a variety of ways, including active targeting [ligand-receptor interactions] and passive targeting [increased permeability and retention effect] [13].
- ii. *Imaging*: Nanoparticles can also be utilized as contrast agents in imaging processes like computed tomography [CT], magnetic resonance imaging [MRI], and optical imaging. These imaging techniques make it possible to see biological activities at the cellular and molecular levels, which help in the early diagnosis of diseases and the evaluation of treatment effectiveness [14].
- iii. *Therapeutics*: Drug delivery systems are just one aspect of nanotechnology-based therapies, which also include other cutting-edge modalities like gene therapy and regenerative medicine. For instance, therapeutic genes or small interfering RNA [siRNA] can be delivered to target cells using nanocarriers, modifying gene expression and curing genetic illnesses [15].
- iv. *Cell-material interaction*: For the creation of secure and efficient nanomedicine applications, understanding the interaction between nanomaterials and biological systems is essential. Studying how nanomaterials affect cell viability, proliferation, and differentiation as well as how they could trigger immunological responses is part of this [16].
- v. *Education and training*: As nanomedicine develops, there is an increasing demand for both in this area. Some colleges provide students with a thorough understanding of the

principles and applications of this developing field by offering courses and programs in nanomedicine. Furthermore, conversations have been had regarding incorporating nanomedicine ideas into regular medical education and professional development programs [17].

- vi. *Nanofabrication Methods*: To produce nanoscale structures and devices, sophisticated nanofabrication methods, such as lithography, self-assembly, and 3D printing, are essential to the development of nanomedicine [18]
- vii. *Biocompatibility*: It is crucial to make sure that nanomaterials are compatible with biological systems. Studies on biocompatibility examine how these substances interact with living things [19].
- viii. *Targeting and Specificity*: A key component of nanomedicine is the achievement of high degrees of targeting and specificity in the delivery of therapeutic substances. Researchers are working to create intelligent nanoparticles that can recognize and communicate only with particular cells or tissues.

From cancer to neurological illnesses, nanomedicine has considerable promise for enhancing the diagnosis and treatment of a variety of diseases. It is anticipated that the field will have a substantial impact on healthcare and medicine as it continues to develop [20].

Role of Chemistry in Nanomedicine

Because it is involved in the design, synthesis, and characterisation of nanomaterials utilized in a variety of applications, chemistry is essential to nanomedicine. The following are some ways that chemistry is involved in nanomedicine:

Chemistry provides the methods and equipment for creating nanoparticles with the necessary surface chemistry, functionality, size, and form. For instance, emulsion, sol-gel, and precipitation processes can all be used to create both organic and inorganic nanoparticles [21].

Nanoparticles' surface chemistry can be adjusted to perform particular tasks, such as medication administration, imaging, and targeting. This entails attaching ligands, antibodies, or other biomolecules to the nanoparticle surface via a variety of chemical techniques, such as covalent and non-covalent functionalization [22].

Analytical techniques for analysing the physicochemical characteristics of nanoparticles, such as size, shape, surface charge, and stability, are provided by chemistry. Transmission electron microscopy [TEM], dynamic light scattering [DLS], zeta potential analysis, and Fourier transform infrared [FTIR] spectroscopy are among the methods used in this. Chemistry is also engaged in the assessment of a material's toxicity, which is important for guaranteeing its safety and effectiveness in biomedical applications. This entails conducting numerous in vitro and in vivo experiments to examine the impact of nanoparticles on cell viability, oxidative stress, inflammation, and genotoxicity. At present, however, there are still major fundamental and technical barriers that need to be understood and overcome. These problems include the complex interactions between nanoparticles and biological systems in vivo, rapid uptake and clearance of nanoparticles by the reticuloendothelial system [RES] organs [such as the liver and spleen], active versus passive targeting, and limited penetration of nanoparticles to solid tumours [see Figure 1]. The complex behaviours of nanoparticles under physiological conditions are still poorly understood, and detailed kinetic and

thermodynamic principles are not available to guide the rational design and development of imaging and therapeutic nanoparticle agents [23].

Chemistry can help with standardization, quality control, and safety evaluation, among other regulatory concerns related to nanomedicine. According to the regulatory needs of various nations, this entails creating rules and processes for the characterisation, testing, and approval of nanomedicine products [24].

In essence, chemistry is the foundation of nanomedicine, providing the knowledge and resources needed to develop and build nanoscale materials and systems that have the potential to completely transform medical imaging, drug delivery, diagnostics, and therapy. Chemistry and nanomedicine working together could greatly boost medical technology and patient outcomes. Due to its potential to enhance treatment outcomes and quicken the transition of nanomedicine from the laboratory to the clinic, AI has grown in significance in the field of nanomedicine [25].

AI can be used to design and optimize nanomaterials and drug delivery systems [DDSS] for desired behaviours and qualities. To forecast the most effective synthetic pathways, ideal reaction parameters, and expected product outputs, machine learning [ML], high-throughput testing, and data science are used. Another area where AI can fully realize the potential of nanomedicine is in the optimization of medication and dosage parameters in combinatorial nanomedicine administration [26]. AI can be used to examine huge datasets derived from a variety of sources, including omics data, electronic sensors, and clinical trials, to find patterns and correlations that can help with medication discovery and customized medicine. In addition, AI can be utilized to create predictive models that mimic how

nanomaterials behave in biological systems, assisting in the DDSs design and improvement. AI can be used to track and evaluate real-time data from therapies based on nanomedicine, giving feedback on the effectiveness, toxicity, and reaction of the drugs. This may make it possible to use personalized medical techniques that modify a patient's care to suit their unique requirements and traits [27]. AI can be utilized to handle standardization, quality control, and safety assessment challenges that are related to regulations for

nanomedicine. To characterize, test, and approve nanomedicine items in compliance with international regulatory standards, we must create AI-based tools and methods. By enabling the design, development, and monitoring of nanomaterials and DDSs with enhanced efficacy, safety, and specificity, AI has the potential to revolutionize nanomedicine. By offering tools and methods for data-driven drug development and personalized treatment, AI can also hasten the transition of nanomedicine from the laboratory to the clinic [28].




Figure 1 Schematic diagram showing the complex behaviours of nanoparticles under in-vivo conditions [23]

The Role of AI in Healthcare

In the healthcare sector, AI has become a disruptive force that is changing how medical practitioners identify, treat, and manage illnesses. In this innovative environment, notable breakthroughs have been made in nanomedicine and AI-enabled diagnostics through the combination of biotechnology and AI [29]. The potential for more precise and tailored healthcare solutions, effective medication development, and better patient outcomes makes this convergence extremely significant. These are a few effects of AI in healthcare, with an emphasis on how biotechnology and AI work together in nanomedicine and AI-enabled diagnostics [30].

Biotechnology in Nanomedicine

- i. *Precision Cancer Medicine:* Nanomaterials are included in the technologies being developed for omics, diagnosis, and treatment. The creation of targeted drug delivery systems, which can be difficult because of patient tumor heterogeneity, is aided by this integration. The combination of AI and nanotechnologies can solve some of the problems associated with targeted medication administration utilizing nanoparticles [NPs] by enabling the quick analysis of massive patient data, forecasting the course of disease, assessing pharmacological profiles, and identifying cancer biomarkers [31].
- ii. *AI-Enabled Nanomedicines:* AI algorithms are employed in the development of nanomedicines for the treatment, monitoring, and diagnosis of cancer. The creation of individualized treatment regimens based on genetic variants connected to particular diseases or therapeutic outcomes is made possible by these

developments in AI-enabled nanomedicines [32].

AI-Enabled Diagnostics

- i. *Improving medical imaging:* It is one of the most prominent uses of AI in healthcare. AI systems have demonstrated great promise in the interpretation of radiological images, including CT, MRI, and X-rays. These photos may be analyzed by deep learning algorithms to identify patterns and abnormalities, which enables quicker and more accurate diagnosis. This has significant effects on treatment planning and early detection. This is complemented by biotechnology, especially in nanomedicine, which makes it possible to create contrast chemicals and nanoparticles that improve the visibility of particular tissues or disease indicators in these pictures [33]. These developments in nanoscale imaging have the potential to greatly increase diagnostic procedure accuracy.
- ii. *Precision Medicine:* AI algorithms can help with individualized treatment decision-making, identify patient subgroups, and predict treatment responses by evaluating patient data, including genomes, proteomics, and clinical records [34]. AI advances precision medicine techniques by aiding in the creation of biomarkers for illness diagnosis and prognosis.

AI-driven Drug Discovery and Design- Discuss How AI Accelerates Drug Discovery and Design in Chemistry

By enabling researchers to quickly evaluate huge data sets, create new compounds, and optimize therapeutic characteristics, AI has the potential to speed up drug discovery and design in chemistry. Here are some examples

of how AI is being applied to the development of pharmaceuticals:

- i. *De novo drug design*: By examining chemical regions that are too big for humans or conventional computer tools to investigate, AI can be utilized to develop novel therapeutic compounds. Designing chemical compounds that are optimized for particular qualities, such as on-target potency, absorption, distribution, metabolism, excretion, and selectivity, entails employing generative and predictive models [35]. AI may also be used to anticipate the 3D protein structure, the impact of a drug on the target, and safety considerations. AI may be used to screen vast chemical libraries for potential medication candidates with high efficacy and low toxicity.
- ii. *Medication screening and validation*: To discover drug-target relationships and forecast the effectiveness of a particular molecule, supervised and unsupervised learning algorithms are used. AI can be used to evaluate therapeutic targets and improve the solubility, stability, and bioavailability of pharmaceuticals [36].
- iii. *Drug prioritization*: After a group of promising drug compounds have been found, AI can be used to rank and order these molecules to determine which ones should be evaluated further. This entails predicting the likelihood of success of a given molecule based on its chemical structure, pharmacological profile, and clinical data using various AI methodologies, such as reinforcement learning and deep learning.
- iv. *Synthesis pathway generation*: AI can be used to create fictitious medicinal molecules and, in some situations, recommend changes to compounds that will make them easier to

produce. This entails employing a variety of AI approaches, such as machine learning and natural language processing, to study chemical interactions and forecast the most effective synthetic pathways [37].

By enabling the quick analysis of massive data sets, the creation of novel drug compounds, and the optimization of therapeutic features, AI has the potential to revolutionize drug discovery and design in chemistry. Through the screening of extensive chemical libraries, the verification of drug targets, and the prioritization of drug candidates for further evaluation, AI can also speed up the drug discovery process [38].

Personalized Medicine and Biomarker Discovery

Precision medicine, also referred to as personalized medicine, tries to modify medical interventions and therapies for specific patients in light of their distinctive clinical characteristics, genetic makeup, and environmental circumstances [39]. By delivering more efficient and tailored therapies while reducing adverse effects, this strategy has the potential to optimize healthcare. Particularly in the identification of biomarkers and the chemical analysis of genetic material, AI is essential to genomics and customized medicine [40]. Here is how AI advances this area: AI plays a key role in the analysis of the enormous volumes of genetic data produced by tools like DNA sequencing. AI algorithms can locate genetic alterations, mutations, and other patterns in the genome that are connected to particular illnesses or reactions to treatment. Based on their genomic data, AI can be used to forecast which patients are most likely to need medicine. This makes it possible for medication and dosage to be individualized, which is essential for enhancing treatment results and lowering unwanted effects [41].

AI can examine massive genomic data sets to find patterns and connections that can help with drug development and personalized therapy [42-44]. This includes establishing genotype-phenotype connections for hereditary disorders and utilizing machine learning algorithms to forecast disease risk based on individual data. A patient's likelihood of contracting a disease, their prognosis, or their reaction to treatment can all be predicted using biomarkers, which are molecular signs. By detecting genetic, epigenetic, or proteomic patterns linked to disease or treatment response, AI may quickly comb through vast datasets to find novel biomarkers. AI may be used to find biomarkers that can be used to track therapy effectiveness and detect diseases early on [45]. This entails analysing intricate genomic and proteomic data sets and locating pertinent biomarkers using a variety of AI techniques, including deep learning and artificial neural networks. AI can be used in precision medicine to create individualized treatment regimens based on patient genomic and clinical data. Based on their DNA, medical history, and family's medical history, this entails applying AI algorithms to find problems inside the specific patient, enabling more explicit and exact diagnosis and therapy [46].

Nanoparticles and Drug Delivery

Drug delivery has been completely transformed by nanoparticles because of their tiny size and special characteristics. By delivering medications to precise target locations within the body, they increase medication effectiveness and lessen unwanted effects [47]. From the design and manufacture of nanoparticles to their activity within the body, AI is a key component in optimizing them for medication delivery. We'll talk about the importance of nanoparticles in medicine delivery in this session, as well as how AI is changing this industry [48].

Smaller than most cells, nanoparticles are made to encapsulate, carry, or release therapeutic compounds like medications, proteins, or genetic components. Their sizes typically range from 1 to 100 nanometers. They can be designed to have particular qualities including focused delivery, controlled medication release, and extended bloodstream circulation [49]. There are various benefits of using nanoparticles in drug delivery:

- a. *Better Drug Solubility*: The restricted solubility of many medications makes it difficult for them to be absorbed and have a therapeutic impact. Hydrophobic drugs can be encapsulated in nanoparticles to increase their solubility and bioavailability.
- b. *Targeted Delivery*: Drugs can be more effectively delivered and less exposed to healthy tissues when nanoparticles are engineered to specifically target cells or tissues.
- c. *regulated Release*: Drugs can be released by nanoparticles in a regulated way, lowering the frequency of medication delivery and enabling prolonged therapeutic benefits.
- d. *Protection of Labile Drugs*: The body can quickly break down certain medications. These medications can be protected from breaking down by nanoparticles until they reach their target.
- e. *Less adverse Effects*: By limiting exposure to healthy tissues, targeted drug delivery lessens adverse effects and enhances patient comfort.

AI in Optimizing Nanoparticles for Drug Delivery

Particularly in the area of optimizing nanoparticles for drug delivery, AI has become a disruptive force in the pharmaceutical and healthcare industries.

With the potential to improve therapeutic agent administration's precision, efficiency, and personalization, the fusion of nanotechnology and AI offers a fresh take on modernizing drug delivery systems [50]. From creating unique-looking nanoparticles to molecular-level medication release control, AI-driven technologies can optimize every aspect of nanoparticle-based drug delivery. The combination of AI and nanomedicine is not only expediting the medication discovery process but also has the potential to improve treatment outcomes while lowering side effects, which will eventually influence how healthcare is delivered in the future [51].

AI has emerged as a powerful tool in the design, optimization, and monitoring of nanoparticles for drug delivery. Here's how AI contributes to this field:

Nanoparticle Design and Material Selection

Material screening is a critical aspect of AI in drug delivery, involving the selection of materials for nanoparticles or drug carriers that meet specific criteria for biocompatibility, stability, and drug loading capacity. AI plays a significant role in material screening by analyzing vast databases of materials, predicting properties like solubility, degradation rate, and surface charge, assessing biocompatibility, optimizing drug-loading capacity, and integrating multiple criteria for material selection [52].

High-throughput screening allows AI to analyze vast databases of materials, saving time and resources. Property prediction models, such as solubility, degradation rate, and surface charge, help in selecting materials with desirable characteristics. Biocompatibility assessment ensures materials do not induce harmful immune responses or toxicity [53].

AI algorithms can optimize drug-loading capacity by considering factors like porosity

and surface area and identifying materials that can encapsulate more drug molecules. Multi-criteria decision analysis integrates factors like cost, ease of manufacturing, and environmental impact to find the most suitable materials for specific drug delivery applications [54].

AI-driven drug discovery platforms can explore and suggest new materials for drug delivery, leading to innovative systems. Data integration from various sources provides a comprehensive view of available materials and their properties. Early-stage screening is particularly useful in drug delivery system development, helping researchers quickly identify materials with potential for further investigation.

The structural design of nanoparticles is crucial for optimizing AI in drug delivery. It influences parameters such as drug loading capacity, drug release kinetics, stability, and targeting specificity. Key aspects of structural design include particle size and shape, surface properties, core-shell structures, and drug encapsulation [55]

Smaller nanoparticles can circulate longer in the bloodstream and penetrate tissues more effectively, while larger ones can penetrate tissues more effectively. Surface properties can be modified to achieve various objectives, such as functionalizing the surface with ligands or influencing interactions with biological systems [56]. Core-shell nanoparticles have a core material that carries the drug and a shell that controls drug release, providing control over drug release kinetics and enabling sustained delivery.

AI plays a significant role in optimizing structural design by exploring design space, selecting the best materials, using predictive modelling, designing targeted targets, personalizing nanoparticles, and optimizing the manufacturing process. AI algorithms can explore vast design spaces, analyze experimental and computational data, and

help select the most promising nanoparticle designs.

AI-driven predictive models can simulate how different structural variations impact drug release kinetics, biodistribution, and overall efficacy, allowing for more efficient design iterations and reducing the need for extensive experimentation [57]. Personalization can also be achieved by analyzing individual patient data and recommending or designing nanoparticles tailored to a patient's unique physiological characteristics.

Drug Release and Pharmacokinetics:

Predictive models are essential in optimizing nanoparticles for drug delivery. They help estimate drug release rates by considering factors like particle size, composition, and surface properties. They also simulate the behavior of nanoparticles within the body, predicting their distribution, metabolization, and interaction with target tissues. They can predict the potential toxic effects of nanoparticles, enabling safer drug delivery systems [58]. They guide the design of nanoparticles with specific ligands or coatings, improving drug delivery efficiency. They optimize formulation by finding the optimal combination of nanoparticle properties, including size, shape, surface charge, and drug loading. They predict the stability and shelf life of nanoparticle-based drug formulations, aiding in the development of long-lasting and effective pharmaceutical products. Predictive models also save time and resources by reducing the need for extensive trial-and-error experiments [59]. They can be customized for specific drugs and patient populations, enabling personalized drug delivery systems.

Pharmacokinetic modelling, when combined with AI, is crucial in optimising nanoparticles for drug delivery. AI can analyze vast amounts of data related to drug properties, nanoparticle characteristics, and patient

factors to predict nanoparticle behavior in the body, aiding in informed decisions about drug delivery optimization. It can also customize drug delivery strategies based on individual patient data, allowing for tailored formulations and optimized treatment outcomes. AI can predict drug-particle interaction, enabling efficient drug delivery to their intended targets. AI can also continuously adapt drug delivery parameters based on real-time patient data, modifying drug release rates to maintain optimal therapeutic levels. AI can use optimization algorithms to find the best nanoparticle characteristics for a particular drug to achieve the desired pharmacokinetic profile, as displayed in Figure 1. AI-driven pharmacokinetic modelling allows for faster and more cost-effective development of nanoparticle-based drug delivery systems, reducing toxicity and side effects early in the drug development process [60]. In addition, AI can assist in generating data for regulatory approval, providing detailed insights into nanoparticles' impact on pharmacokinetics and ensuring compliance with safety and efficacy standards.

Targeted Delivery

- i. AI-driven image analysis is a powerful tool for optimizing nanoparticles for drug delivery. It can accurately identify and quantify parameters like particle size, shape, and distribution, providing crucial insights for optimizing drug carriers. AI can automate quality control processes, reducing human error and enhancing the consistency of nanoparticle production. It can calculate drug loading and encapsulation efficiency, determining the effectiveness of nanoparticles in carrying and releasing drugs [61]. AI can also assess surface modifications, such as coating nanoparticles with specific ligands, and detecting and quantifying their presence, which is vital for

targeted drug delivery. *In vivo* imaging of nanoparticles within the body can help track their distribution and behavior, aiding in optimizing drug delivery strategies. Predictive modelling can be created by AI and image analysis to optimize nanoparticle design, relating image-derived characteristics to drug delivery outcomes. AI-driven image analysis enables high-throughput screening of numerous nanoparticle variations, accelerating the discovery of optimal drug delivery systems. Real-time monitoring of nanoparticle characteristics during drug release allows for real-time adjustments to optimize drug delivery. AI can provide quantitative data that might be challenging to extract manually from complex nanoparticle images, such as fractal dimension, porosity, and surface roughness.

- ii. AI plays a crucial role in optimizing nanoparticles for drug delivery by designing smart drug release profiles that respond to specific triggers. These profiles ensure drugs are released when and where needed in the body. Real-time monitoring is achieved through sensors or imaging techniques, triggering drug release based on the patient's condition. Machine learning algorithms analyze complex data to predict optimal drug release times, adjusting patterns for maximum therapeutic effect [62]. Feedback loops enable closed-loop systems, where data on drug release and patient response is continuously monitored and adjusted to enhance precision and efficiency. AI can optimize drug release based on the specific target site within the body, such as a tumor, by predicting when the target area will be most receptive to treatment. AI can further minimize

off-target effects by controlling drug release more precisely, particularly for drugs with narrow therapeutic windows. Finally, AI can design drug delivery systems tailored to individual patient characteristics, ensuring the right drug release triggers for each case.

Real-Time Monitoring and Nanosensors

Real-time monitoring of biomarkers in the human body is a significant advancement in healthcare, enabling early disease detection, personalized treatment, and precise evaluation of treatment effectiveness [63]. AI-driven nanosensors have emerged as a powerful technology in this field. The significance of AI-driven nanosensors for biomarker tracking lies in their applications, challenges, and prospects. Early disease detection is crucial for conditions like cancer, diabetes, and cardiovascular diseases. Treatment optimization is possible through real-time data, allowing physicians to adjust medications or therapies based on real-time data [64]. Precision medicine is achieved by tailoring medical interventions to individual patients, considering their unique biology and response to treatment. Remote and continuous monitoring is possible with nanosensors, reducing the need for frequent clinic visits. Early detection and optimized treatment can lead to cost savings in healthcare by preventing disease progression and complications [65].

AI-Driven Nanosensors for Biomarker Tracking:

Nanosensors are devices designed at the nanoscale that detect and measure specific biomarkers or physiological parameters. When AI is integrated into these nanosensors, it enhances their capabilities in several ways [66]. These include real-time data processing, pattern recognition, data fusion, anomaly detection, and personalization. AI algorithms

can process data from nanosensors in real-time, providing immediate insights into a patient's health status [67].

AI can also recognize complex patterns in biomarker data, allowing for early disease diagnosis and prediction. Data fusion allows for the integration of data from multiple nanosensors, providing a comprehensive view of a patient's health [68]. Anomaly detection can identify patterns that may indicate disease onset or adverse reactions to treatment.

AI-driven nanosensors have various applications in healthcare, including cancer detection, diabetes management, cardiovascular health, neurological disorders, infectious disease monitoring, drug efficacy, and pregnancy and fetal health [Tang et al., 2022]. These devices can detect cancer biomarkers, analyse data for early diagnosis and treatment, and provide real-time monitoring for drug effectiveness.

Interdisciplinary Collaboration

Many of the most important problems and creative discoveries in today's complex world require knowledge and contributions from a variety of academic fields. Addressing these issues and seizing growth possibilities require interdisciplinary collaboration, which brings together professionals from several sectors [70].

Interdisciplinary collaboration is crucial for complex problem-solving, innovation, and discovery in various fields like climate change, public health crises, and AI ethics. It fosters creativity by combining diverse perspectives and ideas, leading to novel solutions and discoveries. It also provides a holistic understanding of complex issues, allowing for a more thorough grasp of challenges, opportunities, and consequences [71]. Furthermore, interdisciplinary collaboration is essential for addressing grand challenges such as achieving

sustainable development goals and addressing global health disparities, which require solutions that draw on expertise from multiple fields. Overall, interdisciplinary collaboration is essential for tackling complex issues and achieving global health goals [72].

Interdisciplinary collaboration offers several benefits, including providing comprehensive solutions, fostering effective communication, facilitating knowledge transfer, encouraging innovative thinking, and improving decision-making. It allows for the cross-pollination of ideas, leading to breakthroughs and creative problem-solving [73], the synergy between different disciplines encourages cross-pollination of ideas, resulting in breakthroughs and creative problem-solving. Furthermore, interdisciplinary teams can make more informed decisions by considering a wider range of factors and potential impacts, promoting clearer communication and understanding.

Interdisciplinary collaboration has numerous real-world applications in various fields, including healthcare, environmental sustainability, urban planning, education, and aerospace [74]. In healthcare, collaboration between medical doctors, data scientists, and engineers has led to innovations like telemedicine, AI-driven diagnostics, and personalized medicine. In environmental sustainability, collaboration between environmental scientists, engineers, economists, and policy experts addresses climate change and resource conservation. Urban planning involves collaboration between urban planners, architects, sociologists, and environmentalists to create sustainable cities. In education, a collaboration between educators, psychologists, and technology experts develops innovative educational tools [75].

Interdisciplinary collaboration faces several challenges, including communication barriers, establishing common goals, resource allocation, time and workload, effective

leadership, and team dynamics. Communication barriers can be addressed through regular meetings, transparent communication, and shared glossaries [76]. Goals and visions must be established for successful collaboration. Resources may be concentrated within certain fields, but solutions include cross-disciplinary grants, research centres, and initiatives. The complexity of interdisciplinary projects often outweighs the additional investment. Effective leadership and team dynamics are crucial for successful collaboration [77].

Interdisciplinary collaboration is expected to grow as society tackles complex challenges. Prospects include AI and technology, which will aid in analysing vast datasets and identifying patterns. Global issues like climate change, public health, and global security require interdisciplinary solutions. Educational institutions are recognizing the importance of interdisciplinary skills, leading to increased interdisciplinary programs and training. Cross-disciplinary institutions, such as research institutes, will promote collaboration and provide resources for interdisciplinary projects [78].

Surgical Planning and Navigation: Leveraging AI in Anatomical Modeling

The field of surgery has been significantly transformed by the AI integration into the domain of anatomical modelling and surgical planning. This transformation, particularly relevant to anatomists, holds great promise for enhancing the precision and safety of surgical procedures. One of the most compelling applications of advanced technology in healthcare is the integration of AI-driven surgical planning and navigation systems. These systems utilize sophisticated algorithms and real-time imaging to assist surgeons in performing intricate procedures with enhanced precision. For instance, in neurosurgery, AI-powered navigation tools provide surgeons with detailed 3D maps of the brain, enabling them to navigate complex

anatomical structures and minimize the risk of complications. By leveraging AI and advanced imaging techniques, surgical planning and navigation systems have revolutionized the field of surgery, making procedures safer and more effective.

Anatomical Modeling and AI

AI has revolutionized anatomical modelling by providing advanced tools for the detailed and dynamic representation of the human body [79]. With the aid of machine learning algorithms and image analysis, anatomists and surgeons can create intricate 3D models of anatomical structures. These models not only capture the static anatomy but also the dynamic aspects, such as organ movement and blood flow [79]. AI-driven anatomical modelling enables a more comprehensive understanding of the patient's unique anatomy, paving the way for personalized surgical approaches [80].

Precision and Safety in Surgical Planning

Surgical planning is a critical phase in any medical procedure, and AI plays a vital role in enhancing the precision and safety of this process [81]. AI algorithms can analyze patient-specific data, including medical imaging [such as MRI and CT scans], genetic information, and clinical history, to create a holistic view of the patient's health [82]. This information is then integrated into the surgical planning process.

AI systems assist surgeons and anatomists in making informed decisions. They can simulate various surgical scenarios and predict potential complications. For example, AI can model the spread of diseases, such as cancer, to optimize resection boundaries or calculate the best trajectories for surgical instruments to minimize damage to healthy tissues. These capabilities significantly reduce the margin of error and improve surgical outcomes.

Real-time Surgical Navigation

Intraoperative navigation is another area where AI shines. By continuously analyzing real-time data from imaging devices, AI can provide surgical guidance during the procedure. Surgeons can view overlaid anatomical models on their surgical field through augmented reality systems, allowing them to maintain a clear understanding of the patient's anatomy throughout the operation [83].

This real-time navigation assists in maintaining precision and safety by ensuring that the surgeon follows the preoperative plan while adapting to unexpected challenges during the surgery.

Virtual Anatomy Education

Virtual anatomy education has witnessed a significant transformation with the integration of AI technologies. This innovative approach to teaching and learning human anatomy offers numerous benefits to students and educators alike. In this section, we explore how AI is employed in virtual anatomy education and its impact on the educational experience. One exemplary platform that epitomizes the potential of Virtual Anatomy Education is "Complete Anatomy" by 3D4Medical. This application provides users, including medical students, healthcare professionals, and educators, with an immersive 3D experience of the human body. Users can interact with anatomical structures in real time, rotate them in 360 degrees, peel away layers, and delve deep into intricate details. Such an interactive approach not only enhances retention but also fosters a deeper understanding of complex anatomical structures and their interrelationships.

Moreover, "Complete Anatomy" offers various modules and features tailored to different learning needs. For instance,

students can simulate surgical procedures, understand the biomechanics of joints, or explore the physiological functions of organs. The platform's intuitive interface, combined with its detailed graphics and accurate anatomical representation, makes it a valuable tool in modern medical education.

AI-Driven Interactive Learning

AI-powered virtual anatomy education platforms provide students with a highly interactive learning experience. These platforms utilize machine learning algorithms to adapt to individual learning styles and preferences. For example, AI can identify a student's strengths and weaknesses in understanding specific anatomical structures. It then tailors the learning content and quizzes to focus on areas where the student needs improvement. This personalized approach enhances the learning process, allowing students to grasp complex anatomical concepts more effectively [82].

Realistic 3D Models and Simulations

AI plays a crucial role in the creation of realistic 3D anatomical models and simulations. These models provide students with an immersive experience, allowing them to explore the human body from various angles. AI algorithms ensure that these models are not only visually accurate but also functionally representative of human anatomy. Students can virtually dissect organs, observe physiological processes, and practice surgical procedures in a risk-free environment. This hands-on experience fosters a deeper understanding of anatomy [83].

Ethical Considerations in AI-Driven Nanomedicine Diagnostics and Monitoring

The AI integration in nanomedicine, particularly in diagnostics and monitoring,

presents both groundbreaking opportunities and critical ethical challenges.

- i. *Privacy Concerns:* AI systems often require vast amounts of data to train effectively. In healthcare, this data can include sensitive patient information, such as medical histories, genetic data, and diagnostic images. The misuse or unauthorized access to this data can lead to breaches of patient privacy. For instance, de-identified data can sometimes be re-identified, posing a risk to patient confidentiality [84].
- ii. *Data Security:* With the increasing reliance on digital health records and AI-driven diagnostics, ensuring robust cybersecurity measures is paramount. Vulnerabilities in AI systems or the storage of health data can be exploited by malicious actors, leading to data breaches or unauthorized access.
- iii. *Informed Consent:* AI algorithms might make decisions or predictions based on patient data. Ensuring that patients are informed about how their data is used and obtaining their consent is essential. Without proper informed consent procedures, there is a risk of undermining patient autonomy and trust in the healthcare system [85].
- iv. *Potential Biases in AI Algorithms:* AI algorithms, especially those based on machine learning, can inherit biases present in the data they are trained on. If these biases are not addressed, AI systems can produce discriminatory outcomes, leading to disparities in healthcare delivery [86].

Conclusion

In the realm of nanomedicine, the AI integration into diagnostics and monitoring has led to a transformative paradigm shift. AI-driven solutions have played a pivotal role in

enhancing the precision, personalization, and efficiency of healthcare across various domains. Through AI-enabled diagnostics, medical imaging has become more accurate, enabling early disease detection and streamlined treatment planning. Drug delivery systems have been optimized for improved therapeutic efficacy and reduced side effects. The real-time monitoring of biomarkers through AI-driven nanosensors offers early disease detection and personalized treatment strategies. Interdisciplinary collaboration is paramount for addressing complex healthcare challenges, as the convergence of expertise from multiple fields unlocks novel solutions and breakthroughs.

Moreover, AI has revolutionized surgical planning; offering surgeons enhanced tools for precision and safety. Anatomical modelling and virtual anatomy education have evolved into interactive and personalized experiences, boosting student engagement and knowledge retention. The cost-effective nature of AI-enabled virtual anatomy education broadens access to high-quality instruction while respecting ethical and cultural considerations. AI-enabled diagnostics and monitoring in nanomedicine have ushered in a new era of healthcare, characterized by precision, efficiency, and personalization. As AI continues to advance, the possibilities for innovation and improvement in nanomedicine remain limitless, promising better health outcomes for individuals and the healthcare system as a whole. This review article underscores the AI significance in nanomedicine and its potential to transform the future of healthcare.

Suggestions for Forthcoming Research

Directing study efforts towards these areas, the healthcare community can continue to unlock the full potential of AI in nanomedicine while navigating the associated challenges responsibly and ethically.

- i. *Ethical AI Frameworks*: Develop comprehensive ethical guidelines tailored specifically for AI-driven nanomedicine applications, focusing on ensuring patient privacy, transparency in algorithmic decision-making, and addressing potential biases.
- ii. *Enhanced Data Security*: Investigate innovative encryption and cybersecurity measures tailored for AI applications in healthcare to safeguard patient data from potential breaches.
- iii. *Bias Mitigation Techniques*: Delve deeper into advanced machine learning techniques that can proactively identify and mitigate biases in AI algorithms, ensuring equitable healthcare delivery.
- iv. *Patient-Centric AI Development*: Research methodologies to incorporate patient feedback and preferences directly into AI-driven nanomedicine tools, fostering a patient-centric approach to healthcare.
- v. *Real-time Monitoring Advancements*: Explore the next frontier in real-time biomarker tracking using nanosensors, focusing on enhancing sensitivity, specificity, and early detection capabilities.
- vi. *Integration of Virtual Reality*: Study the potential synergies between AI-driven anatomical modelling and virtual reality [VR] technologies for enhanced surgical training and patient education.

Conflict of interest

The authors declare that they have no personal or financial conflicts that could have influenced the research described in this article.

Availability of data

Upon request, data is available.

Acknowledgments

We extend our gratitude to all the authors for their contribution to the success of the research.

ORCID

Odii Peter Egwuatu

<https://orcid.org/0009-0004-0662-9077>

Merit Oluchi Ori

<https://orcid.org/0009-0005-9259-5842>

Humphrey Sam Samuel

<https://orcid.org/0009-0001-7480-4234>

Francis-dominic Makong Ekpan

<https://orcid.org/0009-0009-4822-7005>

References

- [1]Morrow Jr K.J., Bawa R., Wei C., Recent advances in basic and clinical nanomedicine, *Medical Clinics of North America*, 2007, **91**: 805 [Crossref], [Google Scholar], [Publisher]
- [2]Ahmad A., Rashid S., Chaudhary A.A., Alawam A.S., Alghonaim M.I., Raza S.S., Khan R., January. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors, In *Seminars in Cancer Biology*. Academic Press, 2023 [Crossref], [Google Scholar], [Publisher]
- [3]Andronie M., Lăzăroiu G., Iatagan M., Uță C., Ștefănescu R., Coboșatu M., Artificial intelligence-based decision-making algorithms, internet of things sensing networks, and deep learning-assisted smart process management in cyber-physical production systems. *Electronics*, 2021, **10**: 2497 [Crossref], [Google Scholar], [Publisher]
- [4]Ahmad A., Rashid S., Chaudhary A.A., Alawam A.S., Alghonaim M.I., Raza S.S., Khan R., January. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors, In *Seminars in Cancer*

- Biology*. Academic Press, 2023 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [5] Khong J., Wang P., Gan T.R., Ng J., Anh T.T.L., Blasiak A., Kee T., Ho D., The role of artificial intelligence in scaling nanomedicine toward broad clinical impact, In *Nanoparticles for Biomedical Applications*, Elsevier, 2020, 385 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [6] Patel V., Chesmore A., Legner C.M., Pandey S., Trends in workplace wearable technologies and connected-worker solutions for next-generation occupational safety, health, and productivity, *Advanced Intelligent Systems*, 2022, 4: 2100099. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [7] Allen T.M., Ligand-targeted therapeutics in anticancer therapy, *Nature Reviews Cancer*, 2002, 2: 750 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [8] Topol E.J., High-performance medicine: the convergence of human and artificial intelligence, *Nature medicine*, 2019, 25: 44 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [9] Ekpan F.M., Ori M.O., Samuel H.S., Egwuatu O.P., The synergy of AI and Drug delivery: A Revolution in Healthcare, *International Journal of Advanced Biological and Biomedical Research*, 2024, 12:45. [[Crossref](#)], [[Publisher](#)]
- [10] Ori M.O., Ekpan F.M., Samuel H.S., Egwuatu O.P., Integration of Artificial Intelligence in Nanomedicine, *Eurasian Journal of Science and Technology*, 2024, 4:88. [[Crossref](#)], [[Publisher](#)]
- [11] Samuel H.S., Ekpan FM., Revolutionizing Drugs Administration: Techniques in Drug Delivery and Development, *BioEnergy Research*, 2023, 8:000237. [[Crossref](#)], [[Publisher](#)]
- [12] Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R., Nanocarriers as an emerging platform for cancer therapy, *Nano-enabled medical applications*, 2020, 61 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [13] Duncan R., Polymer conjugates as anticancer nanomedicines. *Nature reviews cancer*, 2006, 6: 688 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [14] Whitesides G.M., Nanoscience, nanotechnology, and chemistry, *Small*, 2005, 1:172 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [15] Chen G., Roy I., Yang C., Prasad P.N., Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy, *Chemical reviews*, 2016, 116: 2826 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [16] Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H., In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice, *Nature nanotechnology*, 2007, 2:47 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [17] Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H., In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. *Nature nanotechnology*, 2007, 2: 47 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [18] Weissleder R., Kelly K., Sun E.Y., Shtatland T., Josephson L., Cell-specific targeting of nanoparticles by multivalent attachment of small molecules, *Nature biotechnology*, 2005, 23:1418 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [19] Lee E.S., Na K., Bae Y.H., Polymeric micelle for tumor pH and folate-mediated targeting, *Journal of Controlled Release*, 2003, 91: 103 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [20] Picard F.J., Bergeron M.G., Rapid molecular theranostics in infectious diseases, *Drug discovery today*, 2002, 7: 1092 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

- [21] Astruc D., Introduction to nanomedicine, *Molecules*, 2015, **21**: 4. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [22] Morrow Jr K.J., Bawa R., Wei C., Recent advances in basic and clinical nanomedicine, *Medical Clinics of North America*, 2007, **91**: 805 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [23] Soares S., Sousa J., Pais A., Vitorino C., Nanomedicine: principles, properties, and regulatory issues, *Frontiers in chemistry*, 2018, 360. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [24] Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H., Nanomedicine—challenge and perspectives, *Angewandte Chemie International Edition*, 2009, **48**: 872 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [25] Pautler M., Brenner S., Nanomedicine: promises and challenges for the future of public health, *International journal of nanomedicine*, 2010, 803 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [26] Wong K.K.Y., Liu X.L., Nanomedicine: a primer for surgeons. *Pediatric surgery international*, 2012, **28**, 943 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [27] Ralph J., Akiyama, T., Coleman, H. D., Mansfield S. D., Effects on lignin structure of coumarate 3-hydroxylase downregulation in poplar, *BioEnergy Research*, 2012, **5**:1009. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [28] Venkatraman S., Has nanomedicine lived up to its promise?, *Nanotechnology*, 2014, **25**:372501. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [29] Adir O., Poley M., Chen G., Froim S., Krinsky N., Shklover J., Shainsky-Roitman J., Lammers T., Schroeder A., Integrating artificial intelligence and nanotechnology for precision cancer medicine, *Advanced Materials*, 2020, 32, 1901989. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [30] Naaz S., Asghar A., Artificial intelligence, nano-technology and genomic medicine: The future of anaesthesia. *Journal of Anaesthesiology, Clinical Pharmacology*, 2022, **38**:11. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [31] Ahmad A., Rashid S., Chaudhary A.A., Alawam A.S., Alghonaim M.I., Raza S.S., Khan R., January. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors. In *Seminars in Cancer Biology*. Academic Press, 2023 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [32] Ahmad A., Rashid S., Chaudhary A.A., Alawam A.S., Alghonaim M.I., Raza S.S., Khan R., January. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors. In *Seminars in Cancer Biology*. Academic Press, 2023 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [33] Tang X., The role of artificial intelligence in medical imaging research, *BJR/ Open*, 2019, **2**: 20190031. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [34] Matsushita S., Tachibana K., Kusakabe T., Hirayama R., Tsutsumi Y., Kondoh M., Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval, *Clinical and Translational Science*, 2021, **14**: 806 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [35] Agrahari V., Hiremath P., Challenges associated and approaches for successful translation of nanomedicines into commercial products. *Nanomedicine*, 2017, **12**:819 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [36] Arts J.H., Hadi M., Keene A.M., Kreiling R., Lyon D., Maier M., Michel K., Petry T., Sauer U.G., Warheit D., Wiench K., A critical appraisal of existing concepts for the

grouping of nanomaterials, *Regulatory Toxicology and Pharmacology*, 2014, **70**: 492 [Crossref], [Google Scholar], [Publisher]

[37] Wang W., Craig Z.R., Basavarajappa M.S., Gupta R.K. Flaws J.A., Di (2-ethylhexyl) phthalate inhibits growth of mouse ovarian antral follicles through an oxidative stress pathway. *Toxicology and applied pharmacology*, 2012, **258**: 288 [Crossref], [Google Scholar], [Publisher]

[38] Albanese A., Tang P.S., Chan W.C., The effect of nanoparticle size, shape, and surface chemistry on biological systems. *Annual review of biomedical engineering*, 2012, **14**:1 [Crossref], [Google Scholar], [Publisher]

[39] Liu Y., Miyoshi H., Nakamura M., Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles, *International journal of cancer*, 2007, **120**:2527 [Crossref], [Google Scholar], [Publisher]

[40] Matsushita S., Tachibana K., Kusakabe T., Hirayama R., Tsutsumi Y., Kondoh M., Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval, *Clinical and Translational Science*, 2021, **14**:806 [Crossref], [Google Scholar], [Publisher]

[41] Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J., The big picture on nanomedicine: the state of investigational and approved nanomedicine products, *Nanomedicine: nanotechnology, biology and medicine*, 2013, **9**: 1 [Crossref], [Google Scholar], [Publisher]

[42] Matsushita S., Tachibana K., Kusakabe T., Hirayama R., Tsutsumi Y., Kondoh M., Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval, *Clinical and Translational*

Science, 2021, **14**: 806. [Crossref], [Google Scholar], [Publisher]

[43] Quazi S., Artificial intelligence and machine learning in precision and genomic medicine, *Medical Oncology*, 2022, **39**: 120 [Crossref], [Google Scholar], [Publisher]

[44] Subramanian M., Wojtusciszyn A., Favre L., Boughorbel S., Shan J., Letaief K.B., Pitteloud N., Chouchane L., Precision medicine in the era of artificial intelligence: implications in chronic disease management. *Journal of translational medicine*, 2020, **18**: 1 [Crossref], [Google Scholar], [Publisher]

[45] Uddin M., Wang Y., Woodbury-Smith, M., Artificial intelligence for precision medicine in neurodevelopmental disorders, *NPJ digital medicine*, 2019, **2**: 112. [Crossref], [Google Scholar], [Publisher]

[46] Matsushita S., Tachibana K., Kusakabe T., Hirayama R., Tsutsumi Y., Kondoh M., Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval, *Clinical and Translational Science*, 2021, **14**: 806. [Crossref], [Google Scholar], [Publisher]

[47] Das K.P., Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Frontiers in Medical Technology*, 2023, **4**: 1067144. [Crossref], [Google Scholar], [Publisher]

[48] Serov N., Vinogradov V., Artificial intelligence to bring nanomedicine to life. *Advanced Drug Delivery Reviews*, 2022, **184**: 114194. [Crossref], [Google Scholar], [Publisher]

[49] Rizvi S.A., Saleh A.M., Applications of nanoparticle systems in drug delivery technology, *Saudi pharmaceutical journal*, 2018, **26**: 64 [Crossref], [Google Scholar], [Publisher]

- [50] Tai Z., Huang Y., Zhu Q., Wu W., Yi T., Chen Z., Lu Y., Utility of Pickering emulsions in improved oral drug delivery, *Drug Discovery Today*, 2020, **25**: 2038. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [51] Egorov E., Pieters C., Korach-Rechtman H., Shklover J., Schroeder A., Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems. *Drug Delivery and Translational Research*, 2021, **11**: 345 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [52] Vora L.K., Gholap A.D., Jetha K., Thakur R.R.S., Solanki H.K., Chavda V.P., Artificial intelligence in pharmaceutical technology and drug delivery design, *Pharmaceutics*, 2023, **15**: 1916 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [53] Dreiman G.H., Bictash M., Fish P.V., Griffin L., Svensson F., Changing the HTS paradigm: AI-driven iterative screening for hit finding. *SLAS DISCOVERY: Advancing the Science of Drug Discovery*, 2021, **26**: 257 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [54] Serghini A., Portelli S., Ascher D.B., AI-Driven Enhancements in Drug Screening and Optimization. In *Computational Drug Discovery and Design*, New York, NY: Springer US, 2023, 269 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [55] Baum Z.J., Yu X., Ayala P.Y., Zhao Y., Watkins S.P., Zhou Q., Artificial intelligence in chemistry: current trends and future directions, *Journal of Chemical Information and Modeling*, 2021, **61**: 3197 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [56] Li R.Y., Lin M., Jiang H.Y., Wen S.H., Shen J.T., Huang W.Q., Zhang X.Y., Impact of anxiety or depression symptoms on propofol requirements for sedation in females: a prospective cohort study. *The Journal of Clinical Pharmacology*, 2020, **60**, 1376 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [57] Aksu B., Paradkar A., de Matas M., Özer Ö., Güneri T., York P., A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation, *Pharmaceutical development and technology*, 2013, **18**: 236 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [58] Goh W.Y., Lim C.P., Peh K.K., Subari K., Application of a recurrent neural network to prediction of drug dissolution profiles. *Neural Computing & Applications*, 2002, **10**:311 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [59] Drăgoi E.N., Curteanu S., Fissore D., On the use of artificial neural networks to monitor a pharmaceutical freeze-drying process. *Drying Technology*, 2013, **31**: 72 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [60] Wu X., December. Research and Design of Intelligent Generating Test Paper System. In *2009 International Conference on Computational Intelligence and Software Engineering*, IEEE, 2009, 1 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [61] Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J., Clinical development success rates for investigational drugs, *Nature biotechnology*, 2014, **32**: 40 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [62] Ding M., Eliashberg J., Stremersch S., Innovation and marketing in the pharmaceutical industry. *International series in quantitative marketing*, 2014, **20**:978 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [63] Parolo C., Idili A., Ortega G., Csordas A., Hsu A., Arroyo-Currás N., Yang Q., Ferguson B.S., Wang J., Plaxco K.W., Real-time monitoring of a protein biomarker. *ACS sensors*, 2020, **5**:1877 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [64] Wang C., He T., Zhou H., Zhang Z., Lee C., Artificial intelligence enhanced sensors-enabling technologies to next-generation

healthcare and biomedical platform. *Bioelectronic Medicine*, 2023, **9**:17. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[65] Xiao Y., Zhang Z., Yin S., Ma X., Nanoplasmonic biosensors for precision medicine. *Frontiers in Chemistry*, 2023, **11**. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[66] Nuhn L., Artificial intelligence assists nanoparticles to enter solid tumours. *Nature Nanotechnology*, 2023, **1** [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[67] Qureshi S.A., Aman H., Schirhagl R., Prospects of using machine learning and diamond nanosensing for high sensitivity SARS-CoV-2 diagnosis, *Magnetochemistry*, 2023, **9**: 171 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[68] Lagopati N., Valamvanos T.F., Proutsou V., Karachalios K., Pippa N., Gatou M.A., Vagena I.A., Cela S., Pavlatou E.A., Gazouli M., Efstathiopoulos E., The Role of Nano-Sensors in Breath Analysis for Early and Non-Invasive Disease Diagnosis. *Chemosensors*, 2023, **11**: 317. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[69] Tang N., Zhang R., Zheng Y., Wang J., Khatib M., Jiang X., Zhou C., Omar R., Saliba W., Wu W., Yuan M., Highly efficient self-healing multifunctional dressing with antibacterial activity for sutureless wound closure and infected wound monitoring. *Advanced Materials*, 2022, **34**: 2106842. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[70] Gunawardena S., Weber R., Agosto D.E., Finding that special someone: Interdisciplinary collaboration in an academic context. *Journal of education for library and information science*, 2010, **210** [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[71] Sharma S.K., Mishra M., Mudgal S.K., Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: A systematic review and meta-analysis. *Journal*

of education and health promotion, 2020, **9**. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[72] Pham L.T., Kumar P., Dahana W.D. Nguyen D.H., Promoting global health transdisciplinary research for planetary health: Towards achieving the 2030 Agenda for Sustainable Development. *Journal of Global Health*, 2023, **13**. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[73] Bosch B., Mansell H., Interprofessional collaboration in health care: Lessons to be learned from competitive sports, *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 2015, **148**: 176 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[74] Wang H.H., Charoenmuang M., Knobloch N.A., Tormoehlen R.L., Defining interdisciplinary collaboration based on high school teachers' beliefs and practices of STEM integration using a complex designed system, *International Journal of STEM Education*, 2020, **7**:1 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[75] Samuelson M., Tedeschi P., Aarendonk D., De La Cuesta C., Groenewegen P., February. Improving inter-professional collaboration in Primary Care. In *Position Paper of the European Forum for Primary Care Quality, in Primary Care*, 2012, **20**: 303 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[76] Rawlinson C., Carron T., Cohidon C., Arditi C., Hong Q.N., Pluye P., Peytremann-Bridevaux I., Gilles I., An overview of reviews on interprofessional collaboration in primary care: barriers and facilitators. *International Journal of Integrated Care*, 2021, **21** [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[77] Geraghty S., Oliver K., In the shadow of the ivory tower: Experiences of midwives and nurses undertaking PhDs. *Nurse Education Today*, 2018, **65**: 36 [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

- [78] Josi R., Bianchi M., Brandt S.K., Advanced practice nurses in primary care in Switzerland: an analysis of interprofessional collaboration. *BMC nursing*, 2020, **19**: 1 [Crossref], [Google Scholar], [Publisher]
- [79] Chen X., Agarwal R.K., Shape optimization of airfoils in transonic flow using a multi-objective genetic algorithm. *Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering*, 2014, **228**:1654 [Crossref], [Google Scholar], [Publisher]
- [80] Pregowska A., Perkins M., Artificial Intelligence in Medical Education Part 1: Typologies and Ethical Approaches. Available at SSRN 4576612. [Crossref], [Google Scholar], [Publisher]
- [81] Gumbs A.A., Frigerio I., Spolverato G., Croner R., Illanes A., Chouillard E., Elyan E., Artificial intelligence surgery: How do we get to autonomous actions in surgery?. *Sensors*, 2021, **21**: 5526. [Crossref], [Google Scholar], [Publisher]
- [82] Ahmed Z., Mohamed K., Zeeshan S., Dong X., Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. *Database*, 2020, **2020**:10. [Crossref], [Google Scholar], [Publisher]
- [83] Mavrogenis A.F., Soultanis K., Patapis P., Papagelopoulos P.J., Anterior thigh flap extended hemipelvectomy and spinoiliac arthrodesis. *Surgical Oncology*, 2011, **20**: 215 [Crossref], [Google Scholar], [Publisher]
- [84] Sweeney L., k-anonymity: A model for protecting privacy. *International journal of uncertainty, fuzziness and knowledge-based systems*, 2002, **10**:557 [Crossref], [Google Scholar], [Publisher]
- [85] Mittelstadt B.D., Allo P., Taddeo M., Wachter S., Floridi L., The ethics of algorithms: Mapping the debate. *Big Data & Society*, 2016, **3**:2053951716679679. [Crossref], [Google Scholar], [Publisher]
- [86] Obermeyer Z., Powers B., Vogeli C., Mullainathan S., Dissecting racial bias in an algorithm used to manage the health of populations. *Science*, 2019, **366**: 44.[Crossref], [Google Scholar], [Publisher]